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Abstract
Background: Transforming growth factor-beta 1 (TGF-b1) has been implicated in hyperoxia-induced cell death and
impaired alveolarization in the developing lung. In addition, the c-JunNH2-terminal kinase (JNK) pathway has been
shown to have a role for TGF-b1-mediated effects. We hypothesized that the JNK pathway is an important
regulator of hyperoxia-induced pulmonary responses in the developing murine lung.
Results: We used cultured human lung epithelial cells, fetal rat lung fibroblasts and a neonatal TGF-b1 transgenic
mouse model. We demonstrate that hyperoxia inhibits cell proliferation, activates cell death mediators and causes
cell death, and promotes myofibroblast transdifferentiation, in a dose-dependent manner. Except for fibroblast
proliferation, the effects were mediated via the JNK pathway. In addition, since we observed increased expression
of TGF-b1 by epithelial cells on exposure to hyperoxia, we used a TGF-b1 transgenic mouse model to determine
the role of JNK activation in TGF-b1 induced effects on lung development and on exposure to hyperoxia. We
noted that, in this model, inhibition of JNK signaling significantly improved the spontaneously impaired
alveolarization in room air and decreased mortality on exposure to hyperoxia.
Conclusions: When viewed in combination, these studies demonstrate that hyperoxia-induced cell death,
myofibroblast transdifferentiation, TGF-b1- and hyperoxia-mediated pulmonary responses are mediated, at least in
part, via signaling through the JNK pathway.
Background
Hyperoxia exposure to the developing lung is a critical
factor in the occurrence of the most common chronic
lung disease in neonates, namely bronchopulmonary
dysplasia (BPD) [1]. This is especially important given
the recent trend in non-invasive ventilation of preterm
neonates; hence, bringing the role of hyperoxia (as
opposed to endotracheal tube mechanical ventilation) to
the forefront among the environmental factors contri-
buting to “new” BPD [1-3]. While efforts have been
made to decrease hyperoxia exposure to the developing
lung, the incidence of BPD has actually increased [3].
An improved understanding of the mechanisms of
hyperoxia-induced cell death and lung injury would be
extremely helpful in formulating potential therapeutic
strategies with the goal of ameliorating BPD [3,4].
An important step in this direction would be to under-
stand if varying levels of exposure to hyperoxia [5] have
differential impact on lung cell death mechanisms, and if
so, evaluate potential therapeutic targets. The mitogen-
activated protein kinase (MAPK) signal transduction
pathways are comprised of at least 3 distinct families;
namely, the extra-cellular signal-regulated kinase (ERK),
p38, and c-JunNH2-terminal kinase (JNK) pathways [6].
Although the functions of the JNK pathways are not yet
fully understood, they are known to regulate cell prolif-
eration, differentiation, death and inflammatory
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responses [6]. JNK signaling has been implicated in
hyperoxia-induced pulmonary injury responses [6-10].
One of the molecular mediators implicated in hyper-
oxia-induced cell death and impaired alveolarization in
the developing lung is transforming growth factor-beta
1 (TGF-b1) [11-16], which has also been associated with
human BPD [17]. Another molecule that has been
implicated as a downstream mediator of TGF-b1 signal-
ing in the newborn lung is connective tissue growth fac-
tor (CTGF) [18]. Recently, the JNK pathway has been
implicated for TGF-b1-mediated effects in the develop-
ing lung [19].
Hence, we hypothesized that inhibition of the JNK sig-
naling pathway in in vitro and in vivo models of hyper-
oxia-exposure to the lung would improve survival.
Furthermore, inhibition of the JNK signaling pathway
would mitigate TGF-b1- and hyperoxia-mediated effects
in the developing lung. Our goal was to study cellular
responses on exposure to hyperoxia in the presence of
JNK inhibition (JNKi), using cultured human lung epithe-
lial cells and fetal rat lung fibroblasts. In addition, we
evaluated the responses of lung-specific TGF-b1 overex-
pression in vivo in the developing lung in the presence of
JNKi, with or without hyperoxia. Specifically, we evalu-
ated mortality, cell proliferation, myofibroblast transdif-
ferentiation and markers thereof (i.e. peroxisome
proliferator-activated receptor g (PPARg), adipocyte dif-
ferentiation-related protein (ADRP), fibronectin and
LEF-1), cell death mediators (FAS, FAS-L, caspase 3),
and CTGF expression in our in vitro and in vivo models.
Furthermore, we utilized a newborn (NB) wild type (WT)
murine BPD model to assess the impact of JNKi on
alveolarization.
Results
Hyperoxia-induced A549 cell death and its mediators are
dependent on the JNK pathway
We initially exposed A549 and MLE cells to varying
levels of hyperoxia (40%, 60% and 95% O2) for 24 h and
noted increased cell death, compared to 21% O2, at 24 h.
Importantly, this effect appeared to be dose-dependent
(Figures 1A and 1B; Additional File 1 Table S1). We also
noted increased levels of total and phosphorylated JNK
(P-JNK) protein with increasing levels of hyperoxia
(Additional File 1figure S1). Using the JNK pathway
inhibitor SP600125 in a dose of 5 μM decreased phos-
pho-JNK (Additional File 1figure S1), and was accompa-
nied by a significant increase in cell viability (Figure 1A
and 1B; Additional File 1Table S1). We had similar
results even when we extended the hyperoxia-exposure
period to 48 h (Additional File 1figure S2).
To further characterize the mechanism of hyperoxia-
induced cell death in the A549 cells, we evaluated FAS,
FAS-L, procaspase-3, and cleaved caspase-3. We noted
increased FAS-L and cleaved caspase-3 protein, with
increasing concentrations of hyperoxia (Figures 1C and
1D; Additional File 1figure S3A). Addition of JNKi miti-
gated this process (Figures 1C and 1D; Additional File
1figure S3B). Hence, our data suggests that the hyper-
oxia-induced molecular signals acting via the JNK path-
way could be potential targets for prevention of
hyperoxia-induced lung cell death.
Hyperoxia-induced alveolar interstitial fibroblasts (AIFs)
cell proliferation is not dependent on the JNK pathway
We next examined the effect of hyperoxia on AIF prolif-
eration and whether this was modulated via JNK activa-
tion. Similar to the effect of hyperoxia on epithelial cells,
we noted a significant decrease in AIF proliferation on
exposure to hyperoxia, the effect being much more pro-
found at 48 h vs. 24 h (Figure 2A). There was significant
JNK activation on exposure to hyperoxia, evident at 10
minutes following exposure to hyperoxia and persisting
even at 24 h (Figure 2B). The hyperoxia-induced JNK acti-
vation was also corroborated by immunocytochemistry
(Figure 2C). In contrast to our observations on epithelial
cells, JNKi using SP600125 in a dose of 10 μM did not
block hyperoxia-induced decrease in AIF proliferation
(data not shown).
Hyperoxia-induced AIF-to-Myofibroblast (MYF)
transdifferentiation is dependent on the JNK pathway
Since hyperoxia induces AIF-to-MYF transdifferentiation
[20], we next determined if this process is JNK-dependent.
Exposure to AIF to 95% O2 for 24 h resulted in a marked
decrease (absence) in lipid droplet staining (red fluores-
cence) with a concomitant marked increase in a-SMA
staining (green fluorescence) (Figure 2D), indicating
hyperoxia-induced AIF-to-MYF transdifferentiation. Both
of these changes were remarkably blocked by concomitant
JNKi (1 μM CEP-1347) (Figure 2D), implying JNK’s critical
role in AIF-to-MYF transdifferentiation. JNKi was con-
firmed by Western analysis (Figure 2E). Similar results
were obtained on using the JNK inhibitor, SP600125
(10 μM) (Figure 2F). Hyperoxia-induced decrease in
PPARg and ADRP levels (Figure 2G), and the accompany-
ing increase in fibronectin and LEF-1 levels (Figure 2H),
key indicators of AIF-to-MYF transdifferentiation, were
also blocked by concomitant treatment with JNKi, further
confirming JNK’s role in AIF-to-MYF transdifferentiation.
Hyperoxia-induced epithelial cell death and increased
presence of myofibroblasts have been implicated in the
pathogenesis of BPD [4,21]. Since TGFb1 has been
recognized to be an important mediator in epithelial cell
death and transformation to alveolar myofibroblasts in
BPD [3,22], we also evaluated the role of TGFb1 in vitro
and in developmentally-appropriate in vivo models in
relation to hyperoxia and JNK pathway inhibition.
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TGF-b1 and CTGF expression is increased in A549 lung
cells on exposure to hyperoxia
Since TGF-b1 and CTGF have been shown to be induced
by hyperoxia, we decided to investigate if they were
induced in our in vitro hyperoxia model. TGF-b1 and
CTGF mRNA expression were increased in a dose-
dependent manner in A549 cells exposed to varying con-
centrations of hyperoxia (40%, 60% and 95%) for 24 h
(Figures 3A and 3B).
In vivo inhibition of JNK pathway increases survival in
hyperoxia-exposed NB WT and TGF-b1 TG mice
We used hyperoxia-induced acute lung injury model to
test if the in vitro cell death protective response of the
JNKi could improve animal survival in vivo. We exposed
NB WT and TGF-b1 TG mice on dox water to hyperoxia
(100% O2), with and without JNKi. NB TGF-b1 TG mice
had significantly increased mortality in hyperoxia, com-
pared to litter-mate WT controls (Figure 4). NB WT and
TGF-b1 TG, treated with daily injections of the JNKi had
significantly increased survival in hyperoxia (Figure 4),
compared with their respective controls (WT vs.WT
+JNKi, p < 0.0001; TGF-b1 TG vs. TGF-b1 TG +JNKi,
p = 0.01). Thus, inhibition of the JNK pathway was pro-
tective in terms of survival in the hyperoxia-induced
developing lung injury model.
In vivo inhibition of JNK pathway improves
alveolarization in NB TGF-b1 TG mice in room air (RA)
Earlier reports have highlighted the role of the TGF-b
signaling pathway in alveolarization of the developing
lung. Specifically, the NB TGF-b1 TG mouse lung has
been shown to have impaired alveolarization in RA [13].
To assess the impact of inhibition of the JNK pathway in
this process, we treated with daily injections of the JNK
inhibitor, NB TGF-b1 TG mice on dox water from PN7
to PN10, along with littermate WT controls. As noted in
Figures 5A and 5B, use of JNKi, in the presence of TGF-
b1 activation, improved alveolarization. However, the
phenotype was only partially rescued, as evidenced by
lung morphometry measurements (Figure 5C). We also
confirmed that total and P-JNK protein were increased
with TGF-b1 activation and were decreased in the mice
lung tissue when treated with JNKi (data not shown). To
Figure 1 Effect of JNK inhibition on cell death and it’s mediators in hyperoxia-exposed cells. A549 cells were exposed to 21% up to 95%
O2 and cell viability (trypan blue) was assessed at 24 h (1A). MLE-12 cells were exposed to 21% up to 95% O2 and cell viability (TUNEL assay)
was assessed at 24 h (1B). The noted values represent assessments in a minimum of 4 measurements in each group. Next, A549 cells were
exposed to 21% up to 95% O2 and FAS, FAS-L, procaspase 3 and cleaved caspase 3 proteins were assessed by Western Blot. Independent
experiments were done in the presence of the JNK pathway inhibitor. The ratios of FAS-L and cleaved caspase-3 with b-actin were quantified by
densitometery (1C and 1D). The figures are illustrative of a minimum of 4 experiments. O2: oxygen; JNKi: JNK inhibitor. *P < 0.05, **P ≤ 0.02,
#P ≤ 0.01.
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assess if these changes were secondary to mediators of
the cell death pathway, we evaluated the mRNA expres-
sion of caspase 3, FAS, and FAS-L, in these lungs. We
noted increased caspase 3, FAS, and FAS-L, with expo-
sure to TGF-b1 along with increased expression of
CTGF mRNA in the NB lungs on TGF-b1 activation.
Addition of JNKi blocked this process. We confirmed our
observations by quantification of the expression of
CTGF, caspase-3, FAS and FAS-L, as noted in Figures
6A, B, C, and 6D, respectively. Thus, TGF-b1-induced
impaired alveolarization in RA is mediated, at least in
part, by cell death pathway regulators acting via the JNK
pathway in this in vivo model.
In vivo inhibition of JNK pathway did not impact on BAL
fluid TGF-b1 levels in NB TGF-b1 TG mice in room air
JNK pathway inhibition could alter TGF-b1-induced
effects in the lung by altering the production of TGF-b1
or altering its effector capacity. To clarify this, we com-
pared the levels of human TGF-b1 in BAL fluids from
WT and TG mice treated with JNKi on regular or dox
water, in RA. As can be seen in Figure 7 similar levels
Figure 2 Effect of JNK inhibition on fetal alveolar interstitial fibroblasts (AIF) in hyperoxia. AIF were exposed to 21% up to 95% O2 over
24 h and 48 h, and cell proliferation was assessed by thymidine uptake (2A). Total and P-JNK were assessed (2B) and P-JNK staining was
confirmed by immunocytochemistry (2C). Use of JNKi (CEP-1347) blocked the hyperoxia-induced decrease in lipid droplet staining (red
fluorescence) and an increase in a-SMA staining (green fluorescence), two key markers of AIF-to-MYF transdifferentiation (2D) and diminished P-
JNK (2E). Use of JNKi (SP600125) diminished P-JNK (2F) and blocked the hyperoxia-induced decrease in peroxisome proliferator-activated
receptor g (PPARg) and adipocyte differentiation-related protein (ADRP) levels (2G), and the accompanying increase in fibronectin and LEF-1
levels (2H). O2: oxygen; JNKi: JNK inhibitor (SP600125 for A549 and AIFs, CEP-1347 for AIFs). All values represent a minimum of 4 measurements
in each group and all figures are illustrative of a minimum of 4 experiments. *P < 0.05, **P ≤ 0.02, #P ≤ 0.01.
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of BAL TGF-b1 were seen in TG mice with or without
treatment with JNKi, while on dox water, in RA. These
measurements demonstrate that interventions that inhi-
bit JNK pathway act by altering the TGF-b1 effector
pathway (but not TGF-b1 levels), in our model.
In vivo inhibition of JNK pathway improves
alveolarization in NB WT murine BPD model
As expected, the murine BPD mice lungs had large, sim-
plified alveoli with significantly increased chord lengths
(Figure 8). Interestingly, inhibition of JNK pathway
improved alveolarization (Figure 8). However, as evi-
denced by lung morphometry, the lung phenotype was
only partially rescued. This suggests that hyperoxia-
induced impaired alveolarization is mediated, at least in
part, by regulators acting via the JNK pathway in this in
vivo model, with one of these regulators being TGF-b1.
Discussion
Studies were undertaken to test the hypothesis that the
JNK pathway is an important regulator of hyperoxia-
induced pulmonary responses. These studies demon-
strate that hyperoxia inhibits cell proliferation, stimu-
lates cell death, and alters myofibroblast
transdifferentiation in a dose-dependent manner. These
effects are significantly impacted by inhibiting the JNK
pathway. Furthermore, there is increased expression of
TGF-b1 and CTGF, on exposure to hyperoxia, both of
Figure 4 Survival in hyperoxia. NB TGF-b1 TG and WT liter-mate control mice on dox water, with or without treatment with JNKi, were
exposed to 100% O2 and survival was assessed. The noted values represent assessments in a minimum of 4 animals in each group, of 4
independent experiments. WT: wild type; TGF-b1: transforming growth factor beta; JNKi: JNK inhibitor. #P ≤ 0.01, ##P ≤ 0.001.
Figure 3 Effect of hyperoxia on TGF-b1 and CTGF expression. A549 cells were exposed to 21% up to 95% O2 and TGF-b1 and CTGF were
assessed by semi-quantitative RT-PCR, and their ratio with b-actin quantified by densitometery (3A and 3B). The figures are illustrative of a
minimum of 4 experiments. TGF-b1: transforming growth factor beta; CTGF: connective tissue growth factor; O2: oxygen. *P < 0.05, **P ≤ 0.02, #P
≤ 0.01.
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Figure 5 Effect of JNK inhibition on NB TGF-b1-induced alterations in lung architecture. NB TGF-b1 TG and WT liter-mate control mice on
dox or regular water, with or without treatment with JNKi, were sacrificed at PN10, with activation of TGF-b1 at PN7. H&E staining of lung
histology in low (10X; top row) and high (from inset in upper panel; 20X; bottom row) power magnification is shown demonstrating partial
rescue of altered alveolar architecture of NB TGF-b1 TG mice lungs with JNKi (5A and 5B). The figures are illustrative of a minimum of 4 animals
in each group. Alveolar size, as measured by chord length, confirmed the above observations (5C). Each bar represents the mean ± SEM of a
minimum of three animals. NB: newborn; WT: wild type; TGF-b1: transforming growth factor beta1 transgenic; Reg: regular water; Dox: doxcycline
water; JNKi: JNK inhibitor. #P ≤ 0.01, ##P ≤ 0.001.
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which are known to signal via the JNK pathway. Our
studies also demonstrate that hyperoxia-induced mortal-
ity and alveolarization are improved when the JNK path-
way is inhibited, in the presence of excess TGF-b1 and
CTGF, in the developing lung. When viewed in combi-
nation, these studies demonstrate that hyperoxia-
induced cell death and TGF-b1-mediated pulmonary
responses are mediated via signaling, at least in part,
through the JNK pathway.
In our evaluation of varying concentrations of hyper-
oxia on cell death, all 3 concentrations of hyperoxia sig-
nificantly reduced cell survival, compared to RA. We,
however, could not discern any significant differences
between the 3 concentrations of O2 on cell death. Use of
JNKi was able to restore cell survival to RA values, in all
3 O2 concentrations. MLE-12 cells exposed to 95% O2
had increased cell survival on inhibition of the JNK path-
way [7,23]. Using siRNA against JNK1 in A549 cells
exposed to 95% O2 decreased interleukin-8 expression, a
pro-inflammatory cytokine [8]. Data on cell viability were
not reported in that study [8]. Our data supports the
contention that JNK pathway inhibition has a significant
protective response in lung epithelial cells exposed to
95% O2. In addition, we report the novel finding that
such an effect is also noted at lower concentrations (40%
and 60%) of O2 in our in vitro model.
While hyperoxia-exposed decrease in cell proliferation
in AIF was not impacted upon by JNKi, in line with the
findings of Hashimoto et al in human lung fibroblasts,
we found that AIF to MYF transdifferentiation was
blocked by inhibiting JNK activation [24].
Our studies show that the death-receptor pathway and
the executioner caspase 3 are involved in the process of
hyperoxia-induced epithelial cell death. These data are
supported by an earlier report using MLE-12 cells
exposed to 95% O2 [25]. In addition, we also report the
novel observation that JNKi also impacts FAS-L and cas-
pase-3 protein in A549 lung epithelial cells exposed to
95% O2.
To begin to understand the in vivo relevance of our
findings, we selected TGF-b1 as our cytokine of interest
for a variety of reasons. Firstly, the JNK pathway has
Figure 6 Effect of JNK inhibition on CTGF and cell death pathway mediators in NB TGF-b1-induced lung injury. NB TGF-b1 TG and WT
liter-mate control mice on dox or regular water, with or without treatment with JNKi, were sacrificed at PN10, with activation of TGF-b1 at PN7.
mRNA expression of CTGF, caspase 3, FAS, and FAS-L were assessed. The noted values represent assessments in a minimum of 3 animals in each
group. Independent experiments were done in the presence of the JNK pathway inhibitor. The ratios of CTGF, caspase 3, FAS, and FAS-L with b-
actin were quantified by densitometery (6A-D). The figures are illustrative of a minimum of 3 experiments. NB: newborn; WT: wild type; CTGF:
connective tissue growth factor; TGF-b1: transforming growth factor beta1 transgenic; Reg: regular water; Dox: doxcycline water; JNKi: JNK
inhibitor. #P ≤ 0.01, ##P ≤ 0.001.
Li et al. BMC Cell Biology 2011, 12:54
http://www.biomedcentral.com/1471-2121/12/54
Page 7 of 14
been implicated in TGF-b1 signaling in lung cells
[19,24,26-29], specifically CTGF [19,26,28] and cell death
[19,27] as well as myofibroblast transformation [24]. Sec-
ondly, hyperoxia has been shown to upregulate TGF-b1
in premature rat lungs [30]. Hence, we first confirmed
increased expression of TGF-b1 and CTGF in our
in vitro model, before proceeding to test our hypothesis
in the NB TGF-b1 TG mice.
In the hyperoxia-induced acute lung injury model, JNKi
administration was significantly protective in terms of
survival in NB TGF-b1 TG mice. Importantly, the survi-
val of the NB WT mice treated with JNKi was 100% after
7 days of 100% O2 exposure. This suggests that non-
TGF-b1-dependent, but hyperoxia-induced molecular
mediators signaling via the JNK pathway, are also
involved.
Since TGF-b1 has been implicated in BPD, we used the
lung-specific overexpression model to evaluate the
impact of JNKi on alveolarization. We selected PN7 as
the starting point as the mouse lung is in the alveolar
phase at this time, and hyperoxia-induction of TGF-b1
was noted then [30]. We used a 3-day treatment dura-
tion, as it takes about 48 hours for the TGF-b1 induction
by dox to be sustained in our TG model, as previously
described [13]. Expectedly, as previously described [13],
activation of TGF-b1 resulted in impaired alveolarization.
Figure 7 Effect of JNK inhibition on human TGF-b1 BAL fluid levels. NB TGF-b1 TG and WT liter-mate control mice on dox or regular water,
with or without treatment with JNKi, were sacrificed at PN10, with activation of TGF-b1 at PN7. Bronchoalveolar lavage fluid concentrations of
human TGF-b1 were measured. The noted values represent assessments in a minimum of 3 animals in each group. NB: newborn; WT: wild type;
TGF-b1: transforming growth factor beta1 transgenic; Reg: regular water; Dox: doxcycline water; JNKi: JNK inhibitor; BAL: bronchoalveolar lavage
fluid; h: human. #P ≤ 0.02.
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Inhibition of the JNK pathway was able to improve this
to a significant extent, compared to appropriate controls
(NB WT mice on regular or dox water, and TGF-b1 on
regular water). The improvement in alveolar architecture,
however, was only partially corrected to appropriate con-
trol levels (NB WT mice on regular or dox water, and
TGF-b1 on regular water, all treated with JNKi), as noted
in Figure 5. This could be reflective of the short duration
of treatment with JNKi that was employed.
It is important to point out that JNKi did not signifi-
cantly alter the TGF-b1 levels in the BAL fluid of the
TG mice on dox water (Figure 7). Hence, the effects
noted above with JNKi were due to effects downstream
of TGF-b1 pathway activation.
To further assess the potential for clinical translation,
we used the NB WT murine BPD model and found sig-
nificant, but partial, improvement in lung morphometry
with JNK pathway inhibition.
Interestingly, a recent publication has reported lung-
targeted conditional overexpression of CTGF to have a
phenotype of BPD [31]. This data supports our findings
of increased CTGF on TGF-b1 activation in the NB
lung, which also has a phenotype of BPD [13]. Impor-
tantly, we noted decreased expression of CTGF and cell
death pathway regulators with JNK pathway inhibition
association with improvement of the BPD phenotype in
the NB TGF-b1 TG mice lungs.
In addition to inhibiting JNK, SP600125 also inhibits
ERK 1/2. The evaluation of the role of ERK 1/2 in our
modeling systems was beyond the scope of the present
manuscript. There are few limitations of our study: First,
while A549 cells mimic lung epithelial cells, it is a trans-
formed cell line, and hence, may not mimic the effects of
freshly-isolated lung epithelial cells or in vivo. Second,
the use of different strains of mice, at variable gestational
ages, and different doses of JNK inhibitors can lead to
significantly different results. To illustrate, in contrast to
our findings, the JNK inhibitor SP600125 at a dose of 10
μM, used in lung explants obtained from CD1 mice at
embryonic day 12.5, induced endogenous CTGF expres-
sion, TGFb1-induced CTGF expression, increased DNA
fragmentation and cleaved caspase 3 [19]. Adult JNK1
null mutant mice have been reported to have increased
susceptibility to hyperoxia [6]. Interestingly, in contrast,
the same group of investigators reported that adult JNK1
null mutant mice were resistant to ventilation-induced
lung injury [32]. In addition, adult rats treated with a
JNKi were protected from LPS-induced lung injury [33].
Hence, it is obvious that depending on the specific
experimental conditions, the response to JNK inhibition
can be quite variable.
In addition, another important factor to consider is the
significant developmental regulation in the response of
the developing lung to hyperoxia, versus the adult lung,
Figure 8 Effect of JNK inhibition on lung architecture in the NB WT BPD murine model. NB WT BPD murine model (as described in
Methods) and control mice on regular water, with or without treatment with JNKi, were sacrificed at PN14. Alveolar size, as measured by chord
length, noted a significant improvement in lung alveolarization in the BPD model, with JNK inhibition. Each bar represents the mean ± SEM of a
minimum of four animals. NB: newborn; WT: wild type; BPD: bronchopulmonary dysplasia; JNKi: JNK inhibitor. #P ≤ 0.01, ##P ≤ 0.001.
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as shown by us [34,35] and other investigators [4]. This
can be the potential explanation of the seemingly con-
flicting results of our studies versus those in JNK1 and
JNK2 null mutant adult mice having increased lethality
on exposure to hyperoxia [6]. We did, however use devel-
opmentally-appropriate NB mice for our in vivo work, in
an attempt to mimic human BPD. This brings into focus
the fact that independent confirmation of findings under
appropriate and clinically relevant conditions must be
undertaken, instead of extrapolating from in vitro or
adult lung experimental results [36,37].
Conclusions
A schematic for the proposed mechanism for the effects
noted in our experimental models is shown as Figure 9.
To summarize, our in vitro and in vivo studies
Figure 9 A schematic for the proposed mechanism for the effects noted in our experimental models is shown. Hyperoxia exposure to
the developing murine lung acts on alveolar epithelial cells and interstitial fibroblasts to increase TGF-b1. In alveolar epithelial cells, this leads to
increased CTGF and activation of the Fas-L and caspase-3 mediated cell death pathway. In the alveolar interstitial fibroblasts, TGF-b1 enhances
myofibroblast transdifferentiation. The combined effect of increased cell death and myofibroblast transdifferentiation leads to impaired
alveolarization, resulting in the pulmonary phenotype of larger, simplified alveoli, mimicking human bronchopulmonary dysplasia. JNK pathway
inhibition impacts on downstream effects as shown in the figure. TGF-b1: transforming growth factor beta; JNKi: JNK inhibitor; CTGF: connective
tissue growth factor; Fas-L: Fas-ligand.
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demonstrate a role of the JNK pathway, at least in part, in
hyperoxia-induced cell death, myofibroblast transdifferen-
tiation, TGF-b1- and hyperoxia-mediated pulmonary
responses.
Methods
In vitro experiments
Cell Culture
Human lung adenocarcinoma A549 cells were obtained
from American Type Culture Collection (ATCC, Mana-
ssas, VA) and fetal rat lung (embryonic day 18) AIFs were
isolated and cultured following previously described meth-
ods [20]. Cell were grown in DMEM supplemented with
10% fetal bovine serum, 100 units/ml penicillin and strep-
tomycin (Invitrogen) and maintained at 37°C in 5% CO2.
MLE-12 cells (ATCC, # CRL-2210, Manassas, VA) were
cultured in 2% Fetal Calf Serum Dulbecco’s Modified Eagle
Medium, 100 units/ml penicillin and streptomycin (Invitro-
gen) and maintained at 37°C in humidified normoxic (95%
air and 5% CO2) atmosphere. For different hyperoxia
atmosphere (40%O2 and 5% CO2, 60%O2, 5% CO2 and
95%O2, 5% CO2) cells were placed in a sealed humidified
modular incubator chamber (Billups-Rothenberg Inc.) for
24 and 48 hours time intervals. For the cell count and cell
proliferation experiments, we used 6-well plates. For
mRNA and protein extraction, we used 10 cm dishes.
When appropriate, cells were pretreated with JNK inhibitor
SP600125 (5 or 10 μM) (Calbiochem, USA) or CEP-1347
(1 μM) (a kind gift from Cephalon, West Chester, PA) for
1 h. The doses of these JNKi were based on previous
reports [38-40].
Oxygen exposure
The cultured cells (A549, MLE and fetal rat AIFs) were
then exposed to 21%O2, (+ 5%CO2) or different levels of
hyperoxia (30% or 40%O2 + 5%CO2, 60% O2 + 5%CO2,
95%O2 + 5%CO2). The hyperoxia group was placed in a
sealed humidified hyperoxia chamber for 24 h and/or 48 h.
Cell Death
The viability of the cells was assessed by exclusion of try-
pan blue dye. At least 200 cells per experiment were
counted under the microscope, and expressed as a percen-
tage. A minimum of 3 experiments, each in duplicate,
were conducted.
TUNEL Assay
For the quantification of undergoing apoptosis at single
cell level, TUNEL assay was performed according to
manufacturer’s instructions (Roche Diagnostics). Cells
were pretreated with and without 5 μM of JNKi,
SP600125 (Calbiochem, USA) for 1 hour and subse-
quently exposed to normoxic or different concentrations
of hyperoxia atmosphere. After treatment, cells were
fixed in 4% paraformaldehyde and TUNEL-positive cells
were examined at 200 × magnification using Olympus IX
70 inverted fluorescence microscope.
Cell Proliferation
Cell proliferation was assessed by [3H] thymidine incor-
poration assay.
Analysis of mRNA
RNA was isolated from A549 cells using TRIzol Reagent
(Invitrogen corporation, Carlsbad, CA) according to the
manufacturer’s instructions. RNA samples were then
DNase treated and subjected to semiquantitative RT-PCR.
The primers used for semiquantitative RT-PCR: TGF-b1,
5’-TGCTCTTGTGACAGCAAAGATAA-3’, 5’-CTCTGT
GGAGCTGAAGCAATAGT-3’, CTGF, 5’-CAAAG-
CAGCTGCAAATACCA-3’, 5’-GGCCAAATGTGTCTTC
CAGT-3’, FAS, 5’-ATGCACACTCTGCGATGAAG-3’, 5’-
TTCAGGGTCATCCTGTCTCC-3’, FAS-L 5’-CAT CAC
AAC CAC TCC CAC TG-3’, 5’-GTT CTG CCA GTT C
CT TCT GC-3’, Caspase 3, 5’-AGTCTGACTGGAAAG
CCGAA-3, 5’-AAATTCTAGCTTGTGCGCGT-3’
b-actin, 5’-GTGGGCCGCTCTAGGCACCA-3’, 5’-
TGGCCTTAGGGTTCAGGGGG-3’. mRNA band densi-
ties were measured by densitometry and expressed in
Arbitrary Densitometric Units (ADU), as previously
described [34].
Western Blot
We detected JNK (54 and 46 kD), phospho-JNK (54 and
46 kD), FAS (48 kD), FAS-L (40 kD), Procaspase 3 (35
kD), Cleaved Caspase 3 (17 kD) protein from A549 cells
lysates using Western analysis undertaken with antibodies
that reacted selectively with JNK (catalog #:9252 from Cell
Signaling Technology, Beverly, MA) and phospho-JNK
(catalog #:V7931 from Promega Corp., Madison, WI), FAS
and FAS-L (catalog #: SC7886, SC6237 from Santa Cruz
Biotechnology, Santa Cruz, CA), Procaspase 3 and Cleaved
Caspase 3 (catalog #: 9662, 9661 from Cell Signaling Tech-
nology, Beverly, MA), and with b-actin as control, as pre-
viously described [35]. For the AIFs, the antibodies utilized
were JNK and phospho-JNK (catalog # 9252 and 9251,
respectively, Cell Signaling, Danvers, MA), PPARg (catalog
# sc-7196, Santa Cruz, CA), ADRP [a gift from (late) Dr.
Constantine Londos, NIDDK], fibronectin (catalog # sc-
8422, Santa Cruz, CA), LEF-1 (catalog #, sc-28687, Santa
Cruz, CA). Immunoreactive proteins were visualized using
the Quick Spray Chemiluminescent HRP Antibody Detec-
tion Reagent (Denville Scientific, Metuchen, NJ). The
membranes were exposed to HyBlot CL autoradiography
film (Denville Scientific, Metuchen, NJ). Membranes were
then stripped with Restore Western Blot stripping Buffer
(Thermo Scientific, Rockford, IL) and re-incubated with
primary antibodies reactive with b-Actin (Santa Cruz Bio-
technology, Santa Cruz, CA) as normalization. The inten-
sities of protein bands were quantified by NIH Image/
ImageJ.
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Immunohistochemistry
This was done in AIFs for Phospho-JNK detection, oil-
red-O and a-SMA accordingly to previously described
methods [41].
In vivo experiments
Animals
TGF-b1 transgenic (TG) mice were a kind gift from Jack
Elias, MD and were generated as previously described,
and bred to obtain NB mice [13]. The TG mice had
“human” TGF-b1 targeted to the lung using the CC10
promoter and was “turned on” with maternal exposure to
doxycycline (dox) in the drinking water, leading to trans-
mammary activation in the TG (+) pups, as described
previously [13]. Activation of TGF-b1 effector pathway,
as evidenced by activation of the downstream transducer,
Smad2 and p-Smad2 have been previously reported in
our murine model [13]. For the hyperoxia survival
experiments, all NB mice (TGF-b1 TG and litter-mate
WT controls) were exposed to hyperoxia and maternal
dox water from postnatal day 1 (PN1) to PN7 [34,35].
For the RA experiments, all NB mice (TGF-b1 TG and
litter-mate WT controls) were exposed to maternal dox
or regular water from PN7 to PN10 [13]. All mice were
of the C57/Bl6J strain. All animal work was approved by
the Institutional Animal Care and Use Committee at the
Yale University School of Medicine.
Oxygen exposure
For the NB animals, exposure to hyperoxia (along with
their mothers) was done by placing them in cages in an
airtight Plexiglass chamber (55 × 40 × 50 cm), as described
previously [34,35]. For the NB survival experiments, expo-
sure to 100% oxygen was initiated on PN1 and continued
till PN7. For the NB murine model of BPD, exposure to
100% oxygen was initiated on PN1 and continued till PN4
(vide infra). Two lactating dams were used. They were
alternated in hyperoxia and RA every 24 h. The litter size
was kept limited up to 10-12 pups per dam to control for
the effects of litter size on nutrition and growth.
Throughout the experiment, they were given free access
to food and water. Oxygen levels were constantly moni-
tored. The inside of the chamber was kept at atmospheric
pressure, and mice were exposed to a 12 h light-dark
cycle. We opened the oxygen chamber once a day to
change the mothers and inject the mouse pups with the
JNK inhibitor. We used the JNK inhibitor, SP600125, in
the concentration of 2 μg/μl, dissolved in PBS, and used a
dose of 20 mg/kg/day, given intra-peritoneally. The dose
and route of administration of SP600125 was based on
what has been previously reported [42-44].
For the hyperoxia survival experiments, NB TGF-b1
TG mice on dox water, with or without treatment with
JNKi, were exposed to 100% O2. NB WT liter-mate mice
on dox water, with or without treatment with JNKi,
exposed to 100% O2, were used as controls.
NB Murine BPD model
NB WT mice were exposed to hyperoxia, as noted
above, from PN1-4 (saccular stage of murine lung
development) and allowed to recover in RA for the
next 10 days. Mice were sacrificed on PN14. NB WT
mice lungs at PN14 have the phenotype mimicking
human BPD, as has also been reported by other investi-
gators [45]. For the JNKi experiments, NB mice were
injected daily with the JNK inhibitor (as noted above)
for the 14 days.
Analysis of mRNA
RNA was isolated from frozen lungs using TRIzol
Reagent (Invitrogen corporation, Carlsbad, CA) accord-
ing to the manufacturer’s instructions. RNA samples
were then DNase treated and subjected to semiquantita-
tive RT-PCR. The primers used for semiquantitative
RT-PCR have been noted in the in vitro section of
methods (vide supra).
mRNA band densities were measured by densitometry
and expressed in Arbitrary Densitometric Units (ADU),
as previously described [34].
Histology
Lung tissues obtained from the NB mice from the RA
experiments at PN10, using a standard protocol for lung
inflation (25 cm), were fixed overnight in 10% buffered
formalin [46]. After washing in fresh PBS, fixed tissues
were dehydrated, cleared, and embedded in paraffin by
routine methods. Sections (5 μm) were collected on
Superfrost Plus positively charged microscope slides
(Fisher Scientific Co., Houston, Texas, USA), deparaffi-
nized, and stained with hematoxylin & eosin, as
described previously [35].
Lung Morphometry
Alveolar size was estimated from the mean chord length
of the airspace as described previously [35]. At least
three animals were studied at each time point in the
presence and absence of dox water. Chord length
increases with alveolar enlargement.
Bronchoalveolar lavage (BAL) fluid measurements
BAL fluid measurements of “human” TGF-b1 from the
mice sacrificed at PN10 were done using ELISA (catalog
#: DB100B; R&D Systems Inc., Minneapolis, MN), as
per manufacturer’s instructions.
Statistical analyses
Values are expressed as mean ± SEM or median (25th
-75th centiles). Groups were compared with the Stu-
dent’s two-tailed unpaired t test (with Welch’s correc-
tion for unequal variances), Mann-Whitney test or the
logrank test, using GraphPad Prism 3.0 (GraphPad Soft-
ware, Inc., San Diego, CA), as appropriate. A P <0.05
was considered statistically significant.
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Additional material
Additional file 1: Figures S1-3 and Table S1. The additional file figures
S1-3 show the effect of JNK inhibition on total JNK and phosphorylated-
JNK (P-JNK), cell death and cell death mediators in hyperoxia-exposed
cells. The additional file Table S1 shows the numerical values of cell
death in hyperoxia-exposed cells.
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